4-benzimidazol-2-ylpyridazin-3-one derivatives

US7754713B2 · kind B2 · utility

Assignee

• AVENTIS PHARMA S.A. · FR

Inventors

• Swen Hoelder · London, GB
• Karl Schoenafinger · Alzenau, DE
• David William Will · Schwalbach, DE
• Hans Matter · Langenselbold, DE
• Gunter Muller · Frankfurt am Main, DE
• Cecile Combeau · Fontenay-aux-Roses, FR
• Christine Delaisi · Châteauroux, FR
• Anke Steinmetz · Vitry-sur-Seine, FR
• Ingrid Sassoon · Villejuif, FR

Key dates

• Filing date: Oct 15, 2008
• Grant date: Jul 13, 2010
• Expiry date: Oct 15, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, R1 and R2 are detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals.These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).